A randomised double blind controlled trial of nitazoxanide in intestinal polyparasitism in humans: a Brazilian study

ISRCTN ISRCTN74820169
DOI https://doi.org/10.1186/ISRCTN74820169
Secondary identifying numbers N/A
Submission date
27/06/2008
Registration date
18/09/2008
Last edited
18/09/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Mrs Elisabeth Andrade
Scientific

Rua Padre Vieira, 50/302
Minas Gerais
36025070
Brazil

Phone +55 32 3232 2816
Email ecampos@terra.com.br

Study information

Study designRandomised double blind controlled trial, single centre
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleA randomised double blind controlled trial of nitazoxanide of the treatment in intestinal polyparasitism in humans
Study objectivesNitazoxanide is a drug with an ample spectrum of activity, a superior or equivalent effectiveness to secnidazole and/or albendazole in the treatment of majority of intestinal parasitism in humans, and presents with less adverse effects than the previously cited drugs.
Ethics approval(s)The Committee of Ethics in Research in Human Beings of Propesq/UFJF, dated 15th March 2007 (ref: 063/2007)
Health condition(s) or problem(s) studiedIntestinal polyparasitism
Intervention1. Nitazoxanide = 15 mg/kg/day every 12 hours for children, 500 mg tablet every 12 hours for adults, during three days
2. Secnidazole = 30 mg/kg/day for children and 2 g for adults in one dose
3. Albendazole = 400 mg in one dose (suspension for 400 mg for children, tablets of 400 mg for adults)
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Nitazoxanide, secnidazole, albendazole
Primary outcome measure1. Cure (non-infected) defined as an absence of any species of parasite in the examination of excrements
2. Cure absence (infected) defined as maintenance of the pre-existing parasite

These outcomes will be measured in July and September 2008.
Secondary outcome measuresPrevalence of adverse effects. These outcomes will be measured in July and September 2008.
Overall study start date01/07/2008
Completion date30/09/2008

Eligibility

Participant type(s)Patient
Age groupOther
SexBoth
Target number of participants60
Key inclusion criteria1. Participants more than one year of age, either sex
2. Positive for one or more species of intestinal parasites
3. Rural populations in the Zona da Mata of the State of Minas Gerais (Brazil)
4. Taken care of by the Unified National Health System (SUS)
Key exclusion criteria1. Intestinal obstruction for intestinal parasitisms
2. Pregnant
3. Patients with liver or renal insufficiency
4. Alterations in biliary treatment
5. Patient is using warfarin, aspirin, phenytoin, carbamazepine or valproic acid
Date of first enrolment01/07/2008
Date of final enrolment30/09/2008

Locations

Countries of recruitment

  • Brazil

Study participating centre

Rua Padre Vieira, 50/302
Minas Gerais
36025070
Brazil

Sponsor information

Federal University of Juiz de Fora (Brazil)
University/education

Elisabeth Campos de Andrade
Rua Padre Vieira 50 /302
Minas Gerais
36025-070
Brazil

Website http://lattes.cnpq.br/0143686778100049
ROR logo "ROR" https://ror.org/04yqw9c44

Funders

Funder type

University/education

Federal University of Juiz de Fora (Brazil)

No information available

Farmoquimica S/A (Brazil)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan